个人中心 - 老虎社区

jimzephyr

IP属地：未知

帖子 · 3帖子 · 3
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- jimzephyrjimzephyr
  ·2022-01-01
  Ho hi
  非常抱歉，此主贴已删除
  430 1
  2
  分享
  举报
- jimzephyrjimzephyr
  ·2021-04-28
  Nice, let it keep going up
  AMD rose more than 3% in premarket trading
  AMD rose more than 3% in premarket trading.Q1 net profit exceeded expectations, and revenue rose by
  AMD rose more than 3% in premarket trading
  320 评论
  点赞
  分享
  举报
- jimzephyrjimzephyr
  ·2021-04-15
  Interesting
  Merck ends development of Covid drug it acquired from OncoImmune
  KEY POINTS Merck announced Thursday it will end the development of a Covid-19 drug it acquired from
  Merck ends development of Covid drug it acquired from OncoImmune
  366 评论
  1
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3567332724919443","uuid":"3567332724919443","gmtCreate":1604302960444,"gmtModify":1618496626346,"name":"jimzephyr","pinyin":"jimzephyr","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/0e06fb235e0a39bae550fa602632b2bb","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":8,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":692258164,"gmtCreate":1641003997163,"gmtModify":1641003997235,"author":{"id":"3567332724919443","authorId":"3567332724919443","name":"jimzephyr","avatar":"https://static.tigerbbs.com/0e06fb235e0a39bae550fa602632b2bb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567332724919443","authorIdStr":"3567332724919443"},"themes":[],"htmlText":"Ho hi","listText":"Ho hi","text":"Ho hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/692258164","repostId":"2200744536","repostType":4,"isVote":1,"tweetType":1,"viewCount":430,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":100815154,"gmtCreate":1619599033278,"gmtModify":1634211449820,"author":{"id":"3567332724919443","authorId":"3567332724919443","name":"jimzephyr","avatar":"https://static.tigerbbs.com/0e06fb235e0a39bae550fa602632b2bb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567332724919443","authorIdStr":"3567332724919443"},"themes":[],"htmlText":"Nice, let it keep going up","listText":"Nice, let it keep going up","text":"Nice, let it keep going up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/100815154","repostId":"1186026456","repostType":4,"repost":{"id":"1186026456","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1619597271,"share":"https://www.laohu8.com/m/news/1186026456?lang=&edition=full","pubTime":"2021-04-28 16:07","market":"us","language":"en","title":"AMD rose more than 3% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1186026456","media":"Tiger Newspress","summary":"AMD rose more than 3% in premarket trading.Q1 net profit exceeded expectations, and revenue rose by ","content":"<p>AMD rose more than 3% in premarket trading.Q1 net profit exceeded expectations, and revenue rose by 93% year-on-year.</p><p><img src=\"https://static.tigerbbs.com/3233ac832ae2bb19ac73d8f51a84537d\" tg-width=\"1302\" tg-height=\"833\" referrerpolicy=\"no-referrer\"></p><p><b>AMD Earnings, Revenue Beat in Q1</b></p><p>AMD reported on Tuesday first quarterearningsthat beat analysts' forecasts and revenue that topped expectations.</p><p>AMD announced earnings per share of $0.52 on revenue of $3.45B. Analysts polled by Investing.com anticipated EPS of $0.4357 on revenue of $3.18B.</p><p>AMD shares are up 10% from the beginning of the year, still down 14.11% from its 52 week high of $99.21 set on January 11. They are under-performing the Dow Jones which is up 11.04% from the start of the year.</p><p>AMD follows other major Technology sector earnings this month</p><p>AMD's report follows an earnings beat by Microsoft on Tuesday, who reported EPS of $1.95 on revenue of $41.71B, compared to forecasts EPS of $1.78 on revenue of $41.04B.</p><p>Alphabet C had beat expectations on Tuesday with first quarter EPS of $26.29 on revenue of $55.31B, compared to forecast for EPS of $15.71 on revenue of $51.36B.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMD rose more than 3% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMD rose more than 3% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-04-28 16:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AMD rose more than 3% in premarket trading.Q1 net profit exceeded expectations, and revenue rose by 93% year-on-year.</p><p><img src=\"https://static.tigerbbs.com/3233ac832ae2bb19ac73d8f51a84537d\" tg-width=\"1302\" tg-height=\"833\" referrerpolicy=\"no-referrer\"></p><p><b>AMD Earnings, Revenue Beat in Q1</b></p><p>AMD reported on Tuesday first quarterearningsthat beat analysts' forecasts and revenue that topped expectations.</p><p>AMD announced earnings per share of $0.52 on revenue of $3.45B. Analysts polled by Investing.com anticipated EPS of $0.4357 on revenue of $3.18B.</p><p>AMD shares are up 10% from the beginning of the year, still down 14.11% from its 52 week high of $99.21 set on January 11. They are under-performing the Dow Jones which is up 11.04% from the start of the year.</p><p>AMD follows other major Technology sector earnings this month</p><p>AMD's report follows an earnings beat by Microsoft on Tuesday, who reported EPS of $1.95 on revenue of $41.71B, compared to forecasts EPS of $1.78 on revenue of $41.04B.</p><p>Alphabet C had beat expectations on Tuesday with first quarter EPS of $26.29 on revenue of $55.31B, compared to forecast for EPS of $15.71 on revenue of $51.36B.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMD":"美国超微公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186026456","content_text":"AMD rose more than 3% in premarket trading.Q1 net profit exceeded expectations, and revenue rose by 93% year-on-year.AMD Earnings, Revenue Beat in Q1AMD reported on Tuesday first quarterearningsthat beat analysts' forecasts and revenue that topped expectations.AMD announced earnings per share of $0.52 on revenue of $3.45B. Analysts polled by Investing.com anticipated EPS of $0.4357 on revenue of $3.18B.AMD shares are up 10% from the beginning of the year, still down 14.11% from its 52 week high of $99.21 set on January 11. They are under-performing the Dow Jones which is up 11.04% from the start of the year.AMD follows other major Technology sector earnings this monthAMD's report follows an earnings beat by Microsoft on Tuesday, who reported EPS of $1.95 on revenue of $41.71B, compared to forecasts EPS of $1.78 on revenue of $41.04B.Alphabet C had beat expectations on Tuesday with first quarter EPS of $26.29 on revenue of $55.31B, compared to forecast for EPS of $15.71 on revenue of $51.36B.","news_type":1},"isVote":1,"tweetType":1,"viewCount":320,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":347851905,"gmtCreate":1618487902807,"gmtModify":1634292616907,"author":{"id":"3567332724919443","authorId":"3567332724919443","name":"jimzephyr","avatar":"https://static.tigerbbs.com/0e06fb235e0a39bae550fa602632b2bb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567332724919443","authorIdStr":"3567332724919443"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/347851905","repostId":"1183968578","repostType":4,"repost":{"id":"1183968578","kind":"news","pubTimestamp":1618487325,"share":"https://www.laohu8.com/m/news/1183968578?lang=&edition=full","pubTime":"2021-04-15 19:48","market":"us","language":"en","title":"Merck ends development of Covid drug it acquired from OncoImmune","url":"https://stock-news.laohu8.com/highlight/detail?id=1183968578","media":"cnbc","summary":"KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from","content":"<div>\n<p>KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from biopharmaceutical company OncoImmune.\nMerck disclosed in February that U.S. regulators had asked ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck ends development of Covid drug it acquired from OncoImmune</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck ends development of Covid drug it acquired from OncoImmune\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 19:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from biopharmaceutical company OncoImmune.\nMerck disclosed in February that U.S. regulators had asked ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1183968578","content_text":"KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from biopharmaceutical company OncoImmune.\nMerck disclosed in February that U.S. regulators had asked for more data on the drug to support a potential emergency use authorization.\nDue to \"regulatory uncertainties\" and the time and resources needed to provide the additional data, Merck said it decided to discontinue the development of the drug.\n\nMerckannounced Thursday it will end the development of its experimental drug for patients hospitalized with severe Covid-19 after the Food and Drug Administration asked the company to provide additional data to support an emergency use authorization.\nNew Jersey-based Merck acquired the drug, MK-7110, through its $425 million acquisition of privately held biopharmaceutical company OncoImmune late last year.\nAn interim analysis of clinical trial data suggested the drug improved the chances of recovery for the sickest patients with Covid-19 and reduced the risk of death or respiratory failure.\nHowever, Merck disclosed in February that U.S. regulators had asked for more data on the drug beyond the phase three trial already conducted. At the time, the company said it no longer expected to supply the U.S. with the drug in the first half of 2021.\nNow, due to “regulatory uncertainties” and the time and resources needed to provide the additional data, Merck said it decided to discontinue the development of the drug and instead focus its efforts on advancing its other Covid-19 drug as well as accelerating production of the Johnson & Johnson vaccine.\n“Based on the additional research that would be required – new clinical trials as well as research related to manufacturing at scale – MK-7110 would not be expected to become available until the first half of 2022,” the company said in a press release.\nThe announcement marks another disappointment for Merck in efforts to combat the pandemic.\nIn January, it announced it wouldend the development of its two Covid-19 vaccines. In early trials, both vaccines generated immune responses that were inferior to those seen in people who had recovered from Covid-19 as well as those reported for other vaccines, according to the company.\nWhile Merck is discontinuing MK-7110, the company said it will move forward with its oral antiviral drug, molnupiravir, in a phase three clinical trial testing non-hospitalized patients with Covid-19.\n“We continue to make progress in the clinical development of our antiviral candidate molnupiravir,” Roy Baynes, Merck’s chief medical officer, said in a release. “Data from the dose-finding portion of these studies are consistent with the mechanism of action and provide meaningful evidence for the antiviral potential of the 800 mg dose.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":false}